245 related articles for article (PubMed ID: 9240421)
1. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology.
Arai H; Morikawa Y; Higuchi M; Matsui T; Clark CM; Miura M; Machida N; Lee VM; Trojanowski JQ; Sasaki H
Biochem Biophys Res Commun; 1997 Jul; 236(2):262-4. PubMed ID: 9240421
[TBL] [Abstract][Full Text] [Related]
2. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy.
Borroni B; Malinverno M; Gardoni F; Alberici A; Parnetti L; Premi E; Bonuccelli U; Grassi M; Perani D; Calabresi P; Di Luca M; Padovani A
Neurology; 2008 Nov; 71(22):1796-803. PubMed ID: 18971445
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
[TBL] [Abstract][Full Text] [Related]
4. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.
Noguchi M; Yoshita M; Matsumoto Y; Ono K; Iwasa K; Yamada M
J Neurol Sci; 2005 Oct; 237(1-2):61-5. PubMed ID: 15992827
[TBL] [Abstract][Full Text] [Related]
5. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.
Schoonenboom NS; Reesink FE; Verwey NA; Kester MI; Teunissen CE; van de Ven PM; Pijnenburg YA; Blankenstein MA; Rozemuller AJ; Scheltens P; van der Flier WM
Neurology; 2012 Jan; 78(1):47-54. PubMed ID: 22170879
[TBL] [Abstract][Full Text] [Related]
7. Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.
Barthélemy NR; Gabelle A; Hirtz C; Fenaille F; Sergeant N; Schraen-Maschke S; Vialaret J; Buée L; Junot C; Becher F; Lehmann S
J Alzheimers Dis; 2016; 51(4):1033-43. PubMed ID: 26923020
[TBL] [Abstract][Full Text] [Related]
8. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
[TBL] [Abstract][Full Text] [Related]
9. CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics.
Jeppsson A; Wikkelsö C; Blennow K; Zetterberg H; Constantinescu R; Remes AM; Herukka SK; Rauramaa T; Nagga K; Leinonen V; Tullberg M
J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1117-1123. PubMed ID: 31167811
[TBL] [Abstract][Full Text] [Related]
10. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
[TBL] [Abstract][Full Text] [Related]
11. Pattern of Tau forms in CSF is altered in progressive supranuclear palsy.
Borroni B; Gardoni F; Parnetti L; Magno L; Malinverno M; Saggese E; Calabresi P; Spillantini MG; Padovani A; Di Luca M
Neurobiol Aging; 2009 Jan; 30(1):34-40. PubMed ID: 17709155
[TBL] [Abstract][Full Text] [Related]
12. Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy.
Wagshal D; Sankaranarayanan S; Guss V; Hall T; Berisha F; Lobach I; Karydas A; Voltarelli L; Scherling C; Heuer H; Tartaglia MC; Miller Z; Coppola G; Ahlijanian M; Soares H; Kramer JH; Rabinovici GD; Rosen HJ; Miller BL; Meredith J; Boxer AL
J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):244-50. PubMed ID: 24899730
[TBL] [Abstract][Full Text] [Related]
13. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP.
Josephs KA; Petersen RC; Knopman DS; Boeve BF; Whitwell JL; Duffy JR; Parisi JE; Dickson DW
Neurology; 2006 Jan; 66(1):41-8. PubMed ID: 16401843
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
17. SCRN1: A cerebrospinal fluid biomarker correlating with tau in Alzheimer's disease.
Weiner S; Sauer M; Brinkmalm G; Constantinescu J; Constantinescu R; Gomes BF; Becker B; Nellgård B; Dalla K; Galasko D; Zetterberg H; Blennow K; Gobom J
Alzheimers Dement; 2023 Oct; 19(10):4609-4618. PubMed ID: 36946611
[TBL] [Abstract][Full Text] [Related]
18. A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy.
Urakami K; Mori M; Wada K; Kowa H; Takeshima T; Arai H; Sasaki H; Kanai M; Shoji M; Ikemoto K; Morimatsu M; Hikasa C; Nakashima K
Neurosci Lett; 1999 Jan; 259(2):127-9. PubMed ID: 10025574
[TBL] [Abstract][Full Text] [Related]
19. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
Shea YF; Ha J; Chu LW
Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
[TBL] [Abstract][Full Text] [Related]
20. A combination of CSF tau ratio and midsaggital midbrain-to-pons atrophy for the early diagnosis of progressive supranuclear palsy.
Borroni B; Malinverno M; Gardoni F; Grassi M; Parnetti L; Agosti C; Alberici A; Premi E; Bonuccelli U; Gasparotti R; Calabresi P; Di Luca M; Padovani A
J Alzheimers Dis; 2010; 22(1):195-203. PubMed ID: 20847421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
